Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166

被引：45

作者：

Oba, K ^{[1
]}

Konno, H ^{[1
]}

Tanaka, T ^{[1
]}

Baba, M ^{[1
]}

Kamiya, K ^{[1
]}

Ohta, M ^{[1
]}

Kaneko, T ^{[1
]}

Shouji, T ^{[1
]}

Igarashi, A ^{[1
]}

Nakamura, S ^{[1
]}

机构：

[1] Hamamatsu Univ Sch Med, Dept Surg 2, Hamamatsu, Shizuoka 4313192, Japan

来源：

CANCER LETTERS | 2002年 / 175卷 / 01期

关键词：

MMI-166; colon cancer; liver metastasis; zymography; microvessel density;

D O I：

10.1016/S0304-3835(01)00726-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

MMI-166 is a selective inhibitor of matrix metalloprotemase (MMP)-2 and MMP-9. Mice implanted a human colon cancer orthotopically received 200 mg/kg of MMI-166 orally for 5 weeks. Gelatin zymography demonstrated that the administration of MMI-166 remarkably decreased the active MMP-2 expression. Histological examination revealed that MMI-166 showed prominent effect on reduction of the invasive feature of the cancer cells and showed inhibitory effect on tumor vasculature, resulting in the significant decrease of microvessel density of the implanted tumor and liver metastasis compared with the control group. Conclusively, MMI-166 is a potent antiangiogenic oral agent for a human colon cancer. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：45 / 51

页数：7

共 37 条

[1]

Anderson IC, 1996, CANCER RES, V56, P715

[2]

High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma [J].

Davidson, B ;

Goldberg, I ;

Gotlieb, WH ;

Kopolovic, J ;

Ben-Baruch, G ;

Nesland, JM ;

Berner, A ;

Bryne, M ;

Reich, R .

CLINICAL & EXPERIMENTAL METASTASIS, 1999, 17 (10) :799-808

[3]

DAVIES B, 1993, CANCER RES, V53, P2087

[4]

Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566 [J].

Erlichman, C ;

Adjei, AA ;

Alberts, SR ;

Sloan, JA ;

Goldberg, RM ;

Pitot, HC ;

Rubin, J ;

Atherton, PJ ;

Klee, GG ;

Humphrey, R .

ANNALS OF ONCOLOGY, 2001, 12 (03) :389-395

[5]

Gatto C, 1999, CLIN CANCER RES, V5, P3603

[6]

Development of matrix metalloproteinase inhibitors in cancer therapy [J].

Hidalgo, M ;

Eckhardt, SG .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (03) :178-193

[7]

Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice [J].

Igarashi, N ;

Kubota, T ;

Otani, Y ;

Matsuzaki, SW ;

Watanabe, M ;

Teramoto, T ;

Kumai, K ;

Tamaki, K ;

Tanzawa, K ;

Kobayashi, T ;

Kitajima, M .

JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (01) :116-121

[8]

Itoh T, 1998, CANCER RES, V58, P1048

[9]

Koshiba T, 1998, CANCER, V82, P642, DOI 10.1002/(SICI)1097-0142(19980215)82:4<642::AID-CNCR5>3.0.CO

[10]

2-N

← 1 2 3 4 →